23% Weight Loss! Is Novo Nordisk’s Cagrisema a Failure? скачать в хорошем качестве

23% Weight Loss! Is Novo Nordisk’s Cagrisema a Failure?

In this episode of The Downsized, Christopher Durham breaks down Novo Nordisk’s latest REDEFINE 4 trial results for CagriSema — a next-generation obesity therapy that delivered 23% average weight loss over 84 weeks. On the surface, that level of weight loss sounds like a clear success. But in this head-to-head Phase 3 study comparing CagriSema to tirzepatide at 15 mg, the therapy did not meet its primary goal of demonstrating non-inferiority. In today’s rapidly advancing treatment landscape, that distinction carries real significance. This video explores what the results actually showed, why they matter, and how they reflect a broader shift in obesity treatment. For the first time, new therapies are not simply being judged against placebo, but against each other. That signals progress in the science, while also raising the bar for what counts as success. Christopher shares both the clinical context and the patient perspective, explaining how CagriSema’s dual GLP-1 and amylin mechanism represents a different biological strategy rather than a direct replacement for existing options. With Novo continuing to pursue higher-dose trials and additional data expected from the REDEFINE program, this moment may represent less of a failure and more of a turning point in how future obesity treatments are developed and evaluated. Christopher and his wife Laraine began their own GLP-1 treatment in September 2023 and have since lost more than 150 pounds together. Through The Downsized, they aim to translate complex developments in obesity medicine into clear, real-world insights for people living with the disease. This episode examines what the CagriSema results mean today, and what they could mean for future treatment choice, access, and personalization. For more resources and support, visit thedownsized.org. +++++++++++++++++++++++++++++++++++++++ Get your Hume BodyPod today and use our exclusive Downsized code for up to 20% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... Me Again Iphone GLP-1 App: https://apps.apple.com/us/app/meagain... AMAZON GLP-1 Companion Product Store: https://www.amazon.com/shop/downsized As an Amazon Associate, I earn from qualifying purchases. DOWNSIZED LINKS Website: https://thedownsized.org Be our guest on The Downsized Dish: apply at https://thedownsized.org/downsized-dish/ Https://Thedownsized.Org/ Book The Downsized At Sea Cruise 2026: Https://Thedownsized.Org/Downsized-At... FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 Trial Shockwave 01:36 Redefine 4 Trial Setup 02:59 Results and Noninferiority Miss 05:11 How Cagrisema Works 06:56 Next Studies and FDA Timeline 08:20 Market Reaction and Novo Strategy 10:25 New Benchmark in Obesity Drugs 11:28 Patient View on Choice and Access 14:23 Cost Coverage and Real Access 15:09 Questions and Wrap Up